H Tremlett

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. doi request reprint Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities
    Helen Tremlett
    Dept of Medicine Neurology, rm S178, 2211 Wesbrook Mal, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    J Neurol 256:374-81. 2009
  2. ncbi request reprint Asthma and multiple sclerosis: an inverse association in a case-control general practice population
    H L Tremlett
    Department of Medicine Neurology, University of Wales College of Medicine, Cardiff, Wales, UK
    QJM 95:753-6. 2002
  3. doi request reprint New perspectives in the natural history of multiple sclerosis
    Helen Tremlett
    Faculty of Medicine, Division of Neurology, Multiple Sclerosis Program, University of British Columbia, Vancouver, Canada
    Neurology 74:2004-15. 2010
  4. pmc Impact of multiple sclerosis relapses on progression diminishes with time
    H Tremlett
    Department of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    Neurology 73:1616-23. 2009
  5. doi request reprint Monthly ambient sunlight, infections and relapse rates in multiple sclerosis
    Helen Tremlett
    Faculty of Medicine Neurology, University of British Columbia, Vancouver, B C, Canada
    Neuroepidemiology 31:271-9. 2008
  6. doi request reprint Relapses in multiple sclerosis are age- and time-dependent
    H Tremlett
    Department of Medicine Neurology, rm S178, 2211 Wesbrook Mall, University of British Columbia, Vancouver BCV6T2B5, Canada
    J Neurol Neurosurg Psychiatry 79:1368-74. 2008
  7. doi request reprint Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses
    Helen Tremlett
    Faculty of Medicine Neurology, University of British Columbia, Canada
    Pharmacoepidemiol Drug Saf 17:565-76. 2008
  8. doi request reprint Natural history of secondary-progressive multiple sclerosis
    Helen Tremlett
    Department of Medicine Neurology, rm S159, 2211 Wesbrook Mall, University of British Columbia, Vancouver BC V6T 2B5, Canada
    Mult Scler 14:314-24. 2008
  9. ncbi request reprint Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective
    H L Tremlett
    University of British Columbia, Department of Medicine, Division of Neurology, UBC Hospital, Vancouver, BC, Canada
    Mult Scler 14:94-105. 2008
  10. ncbi request reprint Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients
    H Tremlett
    Faculty of Medicine, Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Neurology 67:1291-3. 2006

Collaborators

Detail Information

Publications27

  1. doi request reprint Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities
    Helen Tremlett
    Dept of Medicine Neurology, rm S178, 2211 Wesbrook Mal, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    J Neurol 256:374-81. 2009
    ..We aimed to examine how this phenomenon impacts on demographic and clinical comparisons made between PP and SPMS...
  2. ncbi request reprint Asthma and multiple sclerosis: an inverse association in a case-control general practice population
    H L Tremlett
    Department of Medicine Neurology, University of Wales College of Medicine, Cardiff, Wales, UK
    QJM 95:753-6. 2002
    ..Compared to controls, multiple sclerosis (MS) (Th1-mediated) has been linked to a reduced risk of allergy and asthma (Th2-mediated), based on patient questionnaire studies and a review of asthma medication...
  3. doi request reprint New perspectives in the natural history of multiple sclerosis
    Helen Tremlett
    Faculty of Medicine, Division of Neurology, Multiple Sclerosis Program, University of British Columbia, Vancouver, Canada
    Neurology 74:2004-15. 2010
    ....
  4. pmc Impact of multiple sclerosis relapses on progression diminishes with time
    H Tremlett
    Department of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    Neurology 73:1616-23. 2009
    ..Current literature is conflicting and focused on early relapses. We investigated the effects of relapses at different stages on disability progression...
  5. doi request reprint Monthly ambient sunlight, infections and relapse rates in multiple sclerosis
    Helen Tremlett
    Faculty of Medicine Neurology, University of British Columbia, Vancouver, B C, Canada
    Neuroepidemiology 31:271-9. 2008
    ..Monthly variation in multiple sclerosis (MS) relapses has been found. The relationship between seasonal environmental factors, infections, serum vitamin D [25(OH)D] and MS relapses is undetermined...
  6. doi request reprint Relapses in multiple sclerosis are age- and time-dependent
    H Tremlett
    Department of Medicine Neurology, rm S178, 2211 Wesbrook Mall, University of British Columbia, Vancouver BCV6T2B5, Canada
    J Neurol Neurosurg Psychiatry 79:1368-74. 2008
    ..To examine the relative relapse-rate patterns over time in a relapsing multiple sclerosis (MS) cohort and to investigate potential predictors of relapse rates and periods of low-relapse activity...
  7. doi request reprint Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses
    Helen Tremlett
    Faculty of Medicine Neurology, University of British Columbia, Canada
    Pharmacoepidemiol Drug Saf 17:565-76. 2008
    ..We examined both levels of non-adherence-stopping IMD and missing doses...
  8. doi request reprint Natural history of secondary-progressive multiple sclerosis
    Helen Tremlett
    Department of Medicine Neurology, rm S159, 2211 Wesbrook Mall, University of British Columbia, Vancouver BC V6T 2B5, Canada
    Mult Scler 14:314-24. 2008
    ..To examine prognosis and risk factors for progression to and from secondary-progressive multiple sclerosis (SPMS)...
  9. ncbi request reprint Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective
    H L Tremlett
    University of British Columbia, Department of Medicine, Division of Neurology, UBC Hospital, Vancouver, BC, Canada
    Mult Scler 14:94-105. 2008
    ..In addition, 46 deaths suspected by the reporter as being related to IMD treatment were detailed as well as three possible drug interactions...
  10. ncbi request reprint Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients
    H Tremlett
    Faculty of Medicine, Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada
    Neurology 67:1291-3. 2006
    ..Abnormal test results were associated with higher body mass index (ALT only), male gender (ALT only), and a relapsing-remitting (vs secondary-progressive) course (ALT and AST only)...
  11. ncbi request reprint Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS
    Helen L Tremlett
    Division of Neurology, Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Center, Canada
    Neurology 61:551-4. 2003
    ..The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%). Gender, disability, and disease duration were identified as factors influencing interruption of IFNbeta therapy...
  12. ncbi request reprint Liver injury associated with the beta-interferons for MS: a comparison between the three products
    Helen L Tremlett
    Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, University of British Columbia, Vancouver, BC, Canada
    Neurology 62:628-31. 2004
    ..005) and were higher than reported in clinical trials. Their relative effect on aminotransferases can be approximated as IFNbeta-1b(subcutaneous [SC]) = IFNbeta-1a(SC) > IFNbeta-1a(IM)...
  13. ncbi request reprint Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes
    Helen L Tremlett
    University of British Columbia, Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, UBC Site, S159 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
    Mult Scler 10:298-301. 2004
    ..However, one patient reaching grade 3 toxicity went on to develop liver failure (previously reported)...
  14. ncbi request reprint Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis
    Helen Tremlett
    Department of Medicine Neurology rm S159, Vancouver Hospital and Health Sciences Centre, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada
    J Neurol 251:1297-303. 2004
    ..However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly...
  15. ncbi request reprint The natural history of primary progressive MS in British Columbia, Canada
    Helen Tremlett
    Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    Neurology 65:1919-23. 2005
    ..The authors examined patient characteristics, disease progression, and associated risk factors in the PP population of British Columbia, Canada...
  16. ncbi request reprint Disability progression in multiple sclerosis is slower than previously reported
    Helen Tremlett
    Department of Medicine Neurology, University of British Columbia, Vancouver, Canada
    Neurology 66:172-7. 2006
    ..To investigate disease progression and risk factors in a large geographically based population with multiple sclerosis (MS), using two different inception points--clinical onset and date of birth...
  17. ncbi request reprint Does the season or month of birth influence disease progression in multiple sclerosis?
    Helen L Tremlett
    Department of Medicine, University of British Columbia, Vancouver, Canada
    Neuroepidemiology 26:195-8. 2006
    ..9-47.4) chance of requiring a cane later than those born in other months. There was some evidence to suggest that the gestational period had a small but long-lasting effect on later disease progression in British Columbia, Canada...
  18. ncbi request reprint Is late-onset multiple sclerosis associated with a worse outcome?
    Helen Tremlett
    Department of Medicine Neurology, rm S159, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    Neurology 67:954-9. 2006
    ..To describe the characteristics of late-onset multiple sclerosis (MS) (LOMS, 50+ years) vs adult-onset MS (AOMS, 16 to <50 years) and examine prognosis and associated risk factors...
  19. doi request reprint High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study
    S Chan
    Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, Canada
    Mult Scler 17:361-7. 2011
    ..Post-marketing studies and case reports have linked beta-interferon (IFN╬▓) treatment with liver enzyme abnormalities and liver injuries in patients with multiple sclerosis (MS). Few predictors of risk exist...
  20. doi request reprint Disease onset in familial and sporadic primary progressive multiple sclerosis
    M Koch
    Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada
    Mult Scler 16:694-700. 2010
    ..Our findings suggest a hereditary component to the disease process of PPMS. It would be worthwhile to identify patients with familial PPMS for future research on disease modifying genes in MS...
  21. doi request reprint Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada
    E Kingwell
    Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
    J Neurol Neurosurg Psychiatry 83:61-6. 2012
    ..To examine mortality and factors associated with survival in a population based multiple sclerosis (MS) cohort...
  22. ncbi request reprint Longitudinal follow-up of "benign" multiple sclerosis at 20 years
    Ana Luiza Sayao
    Department of Medicine Neurology, University of British Columbia, Vancouver, BC, Canada
    Neurology 68:496-500. 2007
    ..To evaluate disease status after 20 years in a cohort defined as "benign multiple sclerosis (MS)" (Expanded Disability Status Scale [EDSS] score < or = 3) at 10 years from onset...
  23. doi request reprint Labor induction and augmentation in women with multiple sclerosis
    E Lu
    Department of Medicine Division of Neurology, Faculty of Medicine, University of British Columbia, Canada
    Mult Scler 19:1182-9. 2013
    ..Fatigue and pelvic organ dysfunction are common among women with multiple sclerosis (MS), which may prolong labor and increase the risk of labor induction and/or augmentation...
  24. pmc Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS
    E Kingwell
    Faculty of Medicine, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, V6T 2B5 Canada
    Neurology 74:1822-6. 2010
    ..Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail...
  25. doi request reprint Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts
    Elaine Kingwell
    Faculty of Medicine Neurology, Multiple Sclerosis Program, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    J Neurol Sci 292:57-62. 2010
    ..001). If early intervention at mild disability levels is warranted in MS, then the extended delays to medical recognition for young adult-onset and PPMS patients must be addressed...
  26. doi request reprint The natural history of primary progressive multiple sclerosis
    Marcus Koch
    Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada
    Neurology 73:1996-2002. 2009
    ..Here, we extend previous analyses in an updated PPMS retrospective cohort study of prevalent cases...
  27. doi request reprint Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs
    E Lu
    Faculty of Medicine, Experimental Medicine Program, University of British Columbia, Vancouver, BC, Canada
    Mult Scler 18:460-7. 2012
    ..The incidence of disease-modifying drug (DMD) exposure during pregnancy in multiple sclerosis (MS) is unknown and limited data exists regarding the potential harm of DMD exposure during pregnancy...